We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

By Overturning 340B Orphan Drug Rule, Court Could Stifle Future HRSA Rulemaking

28 May 2014

InsideHealthPolicy

A Friday court ruling that HRSA overstepped its authority by issuing regulations stating orphan drugs used for off-label treatments are subject to 340B program discounts calls into question the agency's authority to issue a long-awaited "mega-reg" laying out the parameters for the broader drug discount program, some industry sources tell Inside Health Policy. In a win for the drug industry, a U.S. District judge on May 23 overturned HRSA's regulation -- which means that any orphan drug regardless of how it is used is now exempt from the 340B discounts – on the grounds that Congress didn't give HRSA authority to clarify an ACA provision that exempts orphan drugs from 340B expansion facilities.

Read More: By Overturning 340B Orphan Drug Rule, Court Could Stifle Future HRSA Rulemaking

The team

Loading data